KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Depreciation and Depletion (2016 - 2026)

Neogenomics filings provide 17 years of Depreciation and Depletion readings, the most recent being $8.8 million for Q1 2026.

  • On a quarterly basis, Depreciation and Depletion fell 6.26% to $8.8 million in Q1 2026 year-over-year; TTM through Mar 2026 was $35.5 million, a 7.98% decrease, with the full-year FY2025 number at $36.1 million, down 7.75% from a year prior.
  • Depreciation and Depletion hit $8.8 million in Q1 2026 for Neogenomics, roughly flat from $8.8 million in the prior quarter.
  • In the past five years, Depreciation and Depletion ranged from a high of $9.9 million in Q1 2024 to a low of $8.4 million in Q1 2022.
  • Median Depreciation and Depletion over the past 5 years was $9.3 million (2023), compared with a mean of $9.2 million.
  • Biggest five-year swings in Depreciation and Depletion: grew 25.67% in 2022 and later fell 10.83% in 2025.
  • Neogenomics' Depreciation and Depletion stood at $9.5 million in 2022, then rose by 1.06% to $9.6 million in 2023, then grew by 2.6% to $9.8 million in 2024, then fell by 10.83% to $8.8 million in 2025, then increased by 0.19% to $8.8 million in 2026.
  • The last three reported values for Depreciation and Depletion were $8.8 million (Q1 2026), $8.8 million (Q4 2025), and $8.8 million (Q3 2025) per Business Quant data.